G. Pover

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

G. Bodoky, Constanta Timcheva, David R. Spigel et al. · Investigational New Drugs · 2011 · 230 citations

Medicine, Oncology, Pharmacology +13

A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens

John D. Hainsworth, C. Cebotaru, Vladimir Kanarev et al. · Journal of Thoracic Oncology · 2010 · 160 citations · Full text

Medicine, Oncology, Pharmacology +11

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

Jaafar Bennouna, István Láng, Manuel Valladares‐Ayerbes et al. · Investigational New Drugs · 2010 · 139 citations · Full text

Medicine, Oncology, Pharmacology +9

A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)

Jean‐Pascal Machiels, Ramón Salazar, Sylvie Rottey et al. · Journal for ImmunoTherapy of Cancer · 2019 · 104 citations · Full text

Medicine, Oncology, Pharmacology +15

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel/Prednisolone in Patients with Hormone-Refractory Prostate Cancer

J Horti, Anders Widmark, Arnulf Stenzl et al. · Cancer Biotherapy and Radiopharmaceuticals · 2009 · 57 citations

Pharmacy, Pharmacology, Pharmacotherapy +16